You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
Lung Cancer Guideline and Expert Concensus
Since the approval and launch of Vebreltinib in November 2023, it has successively been recommended in multiple authoritative lung cancer guidelines and expert consensus.
-
CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (2025 Edition)
[Key Recommendation]: Vebreltinib is recommended as a Grade I for the first-line and subsequent-line treatment of NSCLC with MET exon 14 skipping alterations at Stage Ⅳ of non-small cell lung cancer.
-
Chinese Medical Association Guidelines for Clinical Diagnosis and Treatment of Lung Cancer (2025 Edition)
[Key Recommendation]: Vebreltinib is recommended for the treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping alterations at Stage Ⅳ.
-
Chinese Guidelines for the Treatment of Stage IV Primary Lung Cancer (2026 Edition)
[Key Recommendation]: Vebreltinib is recommended for patients with NSCLC at Stage IV harboring MET exon 14 skipping alterations (Category 2A recommendation), and newly added as a recommended treatment for patients with advanced NSCLC positive for MET gene amplification (Category 2A recommendation).
-
Chinese Clinical Guidelines for the Diagnosis and Treatment of Brain Metastases in Non-Small Cell Lung Cancer with Driver Mutations (2025 Edition)
[Key Recommendation]:Vebreltinib is currently the only MET inhibitor approved for the treatment of both lung cancer and glioma. For patients with non-small cell lung cancer (NSCLC) brain metastasis harboring MET exon 14 (METex14) skipping mutations, priority should be given to type 1b MET inhibitors with demonstrated intracranial activity, Vebreltinib, Tepotinib, Capmatinib, Glumetinib and Savolitinib (Category 2B Recommendation). For NSCLC patients with brain metastases and MET amplification following resistance to EGFR inhibitors, Vebreltinib achieved an objective response rate (ORR) of up to 66.7%.
